Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag117 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Giammarco Baiardi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Unit, Department of Laboratory Diagnostics, IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy. Hauptthemen laut MEDLINE: Lipoglycopeptides, Anti-Bacterial Agents, Vancomycin, Drug Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Oritavancin is a lipoglycopeptide with sustained bactericidal activity against Gram-positive bacteria due to its prolonged half-life. This Systematic Review aimed to extrapolate, from in vitro/in vivo or clinically study, the most relevant PK/PD target to inform therapeutic drug monitoring-guided oritavancin dose optimization in clinical practice. Materials and methods Following the PRISMA 2020 Statement and adopting the PICO strategy, a comprehensive search was conducted in PubMed, Scopus and Cochrane databases up to September 2025.
Results
Of 186 articles screened, 52 were considered eligible for full-text assessment. Nine studies were included and proceeded with data extraction and synthesis steps. In vitro studies showed a marked concentration-dependent bactericidal activity at fCmax > 4–16 mg/L against different bacterial strains, further confirmed by in vivo animal models (fCmax/MIC > 6 to 14). However, the only identified in-human daily repeated doses study supported the findings of an exposure–response relationship with %fT > MIC as predictive of microbiological and clinical success.
Conclusions
The peculiar pharmacokinetics profile of oritavancin results in a borderline collinearity between the two PK/PD indices fCmax/MIC and %fT > MIC in relation to microbiological and clinical success rates. On the basis of available in vitro/in vivo data supporting concentration-dependent killing activity, a single 1200 mg oritavancin dose should be adequate for most infections. In special patient populations, or when multidose oritavancin regimens are adopted for long-term antibiotic treatment, therapeutic drug monitoring supported by expert clinical pharmacological advice may be valuable to optimize the initial and next-dose strategy (1200 mg or 800 mg) and to define the timing of re-administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory Medicine Unit, Department of Laboratory Diagnostics, IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy.
- Infectious Disease Unit, EO Ospedali Galliera, Genoa 16128, Italy.
- Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, Genoa 16132, Italy.
- Clinical Pharmacology Unit, EO Ospedali Galliera, Genoa 16128, Italy.
- Department of Health Sciences, University of Genoa, Genoa, Italy.
- Hospital Hygiene Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
ORCID-Profile: Giammarco Baiardi, Marina Sartini, Francesca Mattioli
Zitieren
APA
Baiardi, G., Pontali, E., Marini, V., Cristina, M. L., Sartini, M., & Mattioli, F. (2026). Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag117
Vancouver
Baiardi G, Pontali E, Marini V, Cristina ML, Sartini M, Mattioli F. Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag117
BibTeX
@article{Baiardi2026,
author = {Baiardi, Giammarco and Pontali, Emanuele and Marini, Valeria and Cristina, Maria Luisa and Sartini, Marina and Mattioli, Francesca},
title = {Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag117}
}
EUVIMED